Table S28: Percent of IgG+ B cells that are epitope-specific (KO-GT8++) magnitude testing between baseline (V02) and post-baseline frozen PBMC time points for the treatment group, for frozen PBMC samples. Testing was done using Wilcoxon signed-rank test for paired data (two-sided, $\alpha = 0.05$) and p values less than 0.05 are highlighted.

	Number of Pairs	Median (Range)	P Value
20μg			
Wk-4 (V02) vs. Wk4 (V06)	18	0.0014 [0.0000, 0.0050] vs. 0.0528 [0.0149, 0.2292]	<0.0001
Wk-4 (V02) vs. Wk8 (V07)	18	0.0014 [0.0000, 0.0050] vs. 0.0235 [0.0056, 0.1231]	<0.0001
Wk-4 (V02) vs. Wk10 (V08)	17	0.0015 [0.0000, 0.0050] vs. 0.3370 [0.0889, 0.8924]	<0.0001
Wk-4 (V02) vs. Wk16 (V10)	18	0.0014 [0.0000, 0.0050] vs. 0.1499 [0.0341, 0.3737]	<0.0001
100μg			
Wk-4 (V02) vs. Wk4 (V06)	18	0.0009 [0.0000, 0.0028] vs. 0.0724 [0.0241, 0.4719]	<0.0001
Wk-4 (V02) vs. Wk8 (V07)	17	0.0009 [0.0000, 0.0028] vs. 0.0385 [0.0116, 0.1537]	<0.0001
Wk-4 (V02) vs. Wk10 (V08)	17	0.0009 [0.0000, 0.0028] vs. 0.5124 [0.1403, 2.5581]	<0.0001
Wk-4 (V02) vs. Wk16 (V10)	16	0.0009 [0.0000, 0.0028] vs. 0.2482 [0.0305, 0.8489]	<0.0001